Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Velpatasvir +/- Ribavirin in Genotype 3 HCV with Cirrhosis
NCT02781558Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2016
- Primary completion
- Oct 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of velpatasvir in chronic hepatitis C (CHC) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to Any Adverse Event. Started Jul 2016; status: completed.
02
Drugs
velpatasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT02781558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781558.